Trastuzumab Resistance in Patients With HER2-Positive Advanced Breast Cancer: Results From the SONABRE Registry.

Autor: Ibragimova KIE; Department of Medical Oncology, Maastricht University Medical Center, Maastricht, The Netherlands; GROW-School for Oncology and Reproduction, Maastricht University, Maastricht, The Netherlands., Geurts SME; Department of Medical Oncology, Maastricht University Medical Center, Maastricht, The Netherlands; GROW-School for Oncology and Reproduction, Maastricht University, Maastricht, The Netherlands., Laczkó D; Department of Medical Oncology, Maastricht University Medical Center, Maastricht, The Netherlands., Meegdes M; Department of Medical Oncology, Maastricht University Medical Center, Maastricht, The Netherlands; GROW-School for Oncology and Reproduction, Maastricht University, Maastricht, The Netherlands., Erdkamp F; Department of Internal Medicine, Zuyderland Medical Center, Sittard-Geleen, The Netherlands., Heijns JB; Department of Medical Oncology, Amphia, Breda, The Netherlands., Tol J; Department of Medical Oncology, Jeroen Bosch Hospital, Den Bosch, The Netherlands., Vriens BEPJ; Department of Internal Medicine, Catharina hospital, Eindhoven, The Netherlands., Aaldering KNA; Department of Internal Medicine, Laurentius hospital, Roermond, The Netherlands., Dercksen MW; Department of Medical Oncology, Máxima Medical Center, Eindhoven, The Netherlands., Pepels MJAE; Department of Internal Medicine, Elkerliek hospital, Helmond, The Netherlands., Peters NAJB; Department of Internal Medicine, St. Jans Gasthuis, Weert, The Netherlands., van de Winkel LMH; Department of Internal Medicine, St Anna Hospital, Geldrop, The Netherlands., van de Wouw AJ; Department of Internal Medicine, Viecuri Medical Centre, Venlo, The Netherlands., de Fallois A; Department of Medical Oncology, Maastricht University Medical Center, Maastricht, The Netherlands., van Kats MACE; Department of Medical Oncology, Maastricht University Medical Center, Maastricht, The Netherlands; GROW-School for Oncology and Reproduction, Maastricht University, Maastricht, The Netherlands., Tjan-Heijnen VCG; Department of Medical Oncology, Maastricht University Medical Center, Maastricht, The Netherlands; GROW-School for Oncology and Reproduction, Maastricht University, Maastricht, The Netherlands. Electronic address: vcg.tjan.heijnen@mumc.nl.

Publikováno v: Clinical breast cancer [Clin Breast Cancer] 2024 Feb; Vol. 24 (2), pp. 103-111. Date of Electronic Publication: 2023 Nov 02.

Outcomes for the first four lines of therapy in patients with HER2-positive advanced breast cancer: results from the SONABRE registry.

Autor: Ibragimova KIE; Department of Medical Oncology, GROW, School for Oncology and Developmental Biology, Maastricht University Medical Center, Maastricht, PO BOX 5800, 6202 AZ, Maastricht, the Netherlands., Geurts SME; Department of Medical Oncology, GROW, School for Oncology and Developmental Biology, Maastricht University Medical Center, Maastricht, PO BOX 5800, 6202 AZ, Maastricht, the Netherlands., Meegdes M; Department of Medical Oncology, GROW, School for Oncology and Developmental Biology, Maastricht University Medical Center, Maastricht, PO BOX 5800, 6202 AZ, Maastricht, the Netherlands., Erdkamp F; Department of Internal Medicine, Zuyderland Medical Center, Sittard-Geleen, the Netherlands., Heijns JB; Department of Medical Oncology, Amphia, Breda, the Netherlands., Tol J; Department of Medical Oncology, Jeroen Bosch Hospital, Den Bosch, the Netherlands., Vriens BEPJ; Department of Internal Medicine, Catharina Hospital, Eindhoven, the Netherlands., Dercksen MW; Department of Medical Oncology, Máxima Medical Center, Eindhoven, the Netherlands., Aaldering KNA; Department of Internal Medicine, Laurentius Hospital, Roermond, the Netherlands., Pepels MJAE; Department of Internal Medicine, Elkerliek Hospital, Helmond, the Netherlands., van de Winkel L; Department of Internal Medicine, St Anna Hospital, Geldrop, the Netherlands., Peters NAJB; Department of Internal Medicine, Sint Jans Gasthuis Hospital, Weert, the Netherlands., Teeuwen-Dedroog NJA; Department of Medical Oncology, GROW, School for Oncology and Developmental Biology, Maastricht University Medical Center, Maastricht, PO BOX 5800, 6202 AZ, Maastricht, the Netherlands., Vriens IJH; Department of Medical Oncology, GROW, School for Oncology and Developmental Biology, Maastricht University Medical Center, Maastricht, PO BOX 5800, 6202 AZ, Maastricht, the Netherlands., Tjan-Heijnen VCG; Department of Medical Oncology, GROW, School for Oncology and Developmental Biology, Maastricht University Medical Center, Maastricht, PO BOX 5800, 6202 AZ, Maastricht, the Netherlands. vcg.tjan.heijnen@mumc.nl.

Publikováno v: Breast cancer research and treatment [Breast Cancer Res Treat] 2023 Apr; Vol. 198 (2), pp. 239-251. Date of Electronic Publication: 2023 Jan 12.

The initial hormone receptor/HER2 subtype is the main determinator of subtype discordance in advanced breast cancer: a study of the SONABRE registry.

Autor: Meegdes M; Department of Internal Medicine, Division of Medical Oncology, Maastricht University Medical Centre, Maastricht, The Netherlands.; GROW School for Oncology and Developmental Biology, Maastricht University, Maastricht, The Netherlands., Ibragimova KIE; Department of Internal Medicine, Division of Medical Oncology, Maastricht University Medical Centre, Maastricht, The Netherlands.; GROW School for Oncology and Developmental Biology, Maastricht University, Maastricht, The Netherlands., Lobbezoo DJA; Department of Internal Medicine, Division of Medical Oncology, Maastricht University Medical Centre, Maastricht, The Netherlands., Vriens IJH; Department of Internal Medicine, Division of Medical Oncology, Maastricht University Medical Centre, Maastricht, The Netherlands.; GROW School for Oncology and Developmental Biology, Maastricht University, Maastricht, The Netherlands., Kooreman LFS; GROW School for Oncology and Developmental Biology, Maastricht University, Maastricht, The Netherlands.; Department of Pathology, Maastricht University Medical Centre, Maastricht, The Netherlands., Erdkamp FLG; Department of Internal Medicine, Zuyderland Medical Centre, Sittard-Geleen, The Netherlands., Dercksen MW; Department of Internal Medicine, Máxima Medical Centre, Veldhoven, The Netherlands., Vriens BEPJ; Department of Internal Medicine, Catharina Hospital, Eindhoven, The Netherlands., Aaldering KNA; Department of Internal Medicine, Laurentius Hospital, Roermond, The Netherlands., Pepels MJAE; Department of Internal Medicine, Elkerliek Hospital, Helmond, The Netherlands., van de Winkel LMH; Department of Internal Medicine, St Anna Hospital, Geldrop, The Netherlands., Tol J; Department of Internal Medicine, Jeroen Bosch Ziekenhuis, Den Bosch, The Netherlands., Heijns JB; Department of Internal Medicine, Amphia Hospital, Breda, The Netherlands., van de Wouw AJ; Department of Internal Medicine, Viecuri Medical Centre, Venlo, The Netherlands., Peters NAJB; Department of Internal Medicine, St. Jans Gasthuis, Weert, The Netherlands., Hochstenbach-Waelen A; Department of Internal Medicine, Division of Medical Oncology, Maastricht University Medical Centre, Maastricht, The Netherlands., Smidt ML; GROW School for Oncology and Developmental Biology, Maastricht University, Maastricht, The Netherlands.; Department of Surgery, Maastricht University Medical Centre, Maastricht, The Netherlands., Geurts SME; Department of Internal Medicine, Division of Medical Oncology, Maastricht University Medical Centre, Maastricht, The Netherlands.; GROW School for Oncology and Developmental Biology, Maastricht University, Maastricht, The Netherlands., Tjan-Heijnen VCG; Department of Internal Medicine, Division of Medical Oncology, Maastricht University Medical Centre, Maastricht, The Netherlands. vcg.tjan.heijnen@mumc.nl.; GROW School for Oncology and Developmental Biology, Maastricht University, Maastricht, The Netherlands. vcg.tjan.heijnen@mumc.nl.

Publikováno v: Breast cancer research and treatment [Breast Cancer Res Treat] 2022 Apr; Vol. 192 (2), pp. 331-342. Date of Electronic Publication: 2022 Jan 13.

Survival before and after the introduction of pertuzumab and T-DM1 in HER2-positive advanced breast cancer, a study of the SONABRE Registry.

Autor: Ibragimova KIE; Department of Medical Oncology, Maastricht University Medical Center, PO BOX 5800, 6202 AZ, Maastricht, The Netherlands.; GROW-School for Oncology and Developmental Biology, Maastricht University, Maastricht, The Netherlands., Geurts SME; Department of Medical Oncology, Maastricht University Medical Center, PO BOX 5800, 6202 AZ, Maastricht, The Netherlands.; GROW-School for Oncology and Developmental Biology, Maastricht University, Maastricht, The Netherlands., Croes S; Department of Medical Oncology, Maastricht University Medical Center, PO BOX 5800, 6202 AZ, Maastricht, The Netherlands., Erdkamp F; Department of Internal Medicine, Zuyderland Medical Center, Sittard-Geleen, The Netherlands., Heijns JB; Department of Medical Oncology, Amphia, Breda, The Netherlands., Tol J; Department of Medical Oncology, Jeroen Bosch Hospital, Den Bosch, The Netherlands., Vriens BEPJ; Department of Internal Medicine, Catharina Hospital, Eindhoven, The Netherlands., Aaldering KNA; Department of Internal Medicine, Laurentius Hospital, Roermond, The Netherlands., Dercksen MW; Department of Medical Oncology, Máxima Medical Center, Eindhoven, The Netherlands., Pepels MJAE; Department of Internal Medicine, Elkerliek Hospital, Helmond, The Netherlands., Peters NAJB; Department of Internal Medicine, Sint Jans Gasthuis, Weert, The Netherlands., van de Winkel L; Department of Internal Medicine, St Anna Hospital, Geldrop, The Netherlands., Tilli DJP; Department of Medical Oncology, Maastricht University Medical Center, PO BOX 5800, 6202 AZ, Maastricht, The Netherlands., Vriens IJH; Department of Medical Oncology, Maastricht University Medical Center, PO BOX 5800, 6202 AZ, Maastricht, The Netherlands.; GROW-School for Oncology and Developmental Biology, Maastricht University, Maastricht, The Netherlands., de Boer M; Department of Medical Oncology, Maastricht University Medical Center, PO BOX 5800, 6202 AZ, Maastricht, The Netherlands.; GROW-School for Oncology and Developmental Biology, Maastricht University, Maastricht, The Netherlands., Tjan-Heijnen VCG; Department of Medical Oncology, Maastricht University Medical Center, PO BOX 5800, 6202 AZ, Maastricht, The Netherlands. vcg.tjan.heijnen@mumc.nl.; GROW-School for Oncology and Developmental Biology, Maastricht University, Maastricht, The Netherlands. vcg.tjan.heijnen@mumc.nl.

Publikováno v: Breast cancer research and treatment [Breast Cancer Res Treat] 2021 Jul; Vol. 188 (2), pp. 571-581. Date of Electronic Publication: 2021 Mar 20.

The relative effectiveness of eribulin for advanced breast cancer treatment: a study of the southeast Netherlands advanced breast cancer registry.

Autor: Pouwels XGLV; Department of Clinical Epidemiology and Medical Technology Assessment (KEMTA), Maastricht University Medical Centre, Maastricht, The Netherlands.; Care and Public Health Research Institute (CAPHRI), Maastricht University, Maastricht, The Netherlands.; School of Oncology and Developmental Biology (GROW), Maastricht University, Maastricht, The Netherlands., Geurts SME; School of Oncology and Developmental Biology (GROW), Maastricht University, Maastricht, The Netherlands.; Division Medical Oncology, Maastricht University Medical Centre, Maastricht, The Netherlands., Ramaekers BLT; Department of Clinical Epidemiology and Medical Technology Assessment (KEMTA), Maastricht University Medical Centre, Maastricht, The Netherlands., Erdkamp F; Department of Internal Medicine, Zuyderland Medical Centre, Sittard-Geleen, The Netherlands., Vriens BEPJ; Department of Internal Medicine, Catharina Hospital, Eindhoven, The Netherlands., Aaldering KNA; Department of Internal Medicine, Laurentius Hospital, Roermond, The Netherlands., van de Wouw AJ; Department of Internal Medicine, VieCuri Medical Center, Venlo, The Netherlands., Dercksen MW; Department of Internal Medicine, Máxima Medical Centre, Veldhoven/Eindhoven, The Netherlands., Smilde TJ; Department of Internal Medicine, Jeroen Bosch Hospital, Hertogenbosch, The Netherlands., Peters NAJB; Department of Internal Medicine, Sint Jans Gasthuis, Weert, The Netherlands., Riel JMV; Department of Internal Medicine, Elisabeth-TweeSteden Hospital, Tilburg, The Netherlands., Pepels MJ; Department of Internal Medicine, Elkerliek Hospital, Helmond, The Netherlands., Heijnen-Mommers J; School of Oncology and Developmental Biology (GROW), Maastricht University, Maastricht, The Netherlands.; Division Medical Oncology, Maastricht University Medical Centre, Maastricht, The Netherlands., Joore MA; Department of Clinical Epidemiology and Medical Technology Assessment (KEMTA), Maastricht University Medical Centre, Maastricht, The Netherlands.; Care and Public Health Research Institute (CAPHRI), Maastricht University, Maastricht, The Netherlands., Tjan-Heijnen VCG; School of Oncology and Developmental Biology (GROW), Maastricht University, Maastricht, The Netherlands.; Division Medical Oncology, Maastricht University Medical Centre, Maastricht, The Netherlands., de Boer M; School of Oncology and Developmental Biology (GROW), Maastricht University, Maastricht, The Netherlands.; Division Medical Oncology, Maastricht University Medical Centre, Maastricht, The Netherlands.

Publikováno v: Acta oncologica (Stockholm, Sweden) [Acta Oncol] 2020 Jan; Vol. 59 (1), pp. 82-89. Date of Electronic Publication: 2019 Oct 04.